# OnCo record nct07216703 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07216703/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07216703", "NCT07216703" ;
  schema:name "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc"@en ;
  schema:alternateName "TroFuse-036"@en ;
  schema:description "A phase 3 trial of Pembrolizumab, Sacituzumab tirumotecan, Bevacizumab in cervical cancer, run by Merck Sharp & Dohme LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07216703/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07216703> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2026-01-19" ;
  onco:cancers <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/merck/> .